Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992261 · ClinicalTrials.gov registry record · Phase 4
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
A Phase 4 study of Plaque Psoriasis, sponsored by Mayne Pharma International Pty.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 11
- Study locations
NCT03992261 is a Phase 4 study of Plaque Psoriasis that has completed, run by Mayne Pharma International Pty. The registered enrollment target is 24 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 3 states.
The verdict
NCT03992261, a Phase 4 study of Plaque Psoriasis, has completed, sponsored by Mayne Pharma International Pty.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.
Conditions Studied
Interventions
- DRUG Halobetasol Topical Foam
Study Locations (11)
Other
- Investigative Site 9 - Batumi
- Investigative Site 10 - Tbilisi
- Investigative Site 11 - Tbilisi
- Investigative Site 3 - Krakow
- Investigative Site 5 - Tarnów
- Investigative Site 4 - Warsaw
- Investigative Site 8 - Rivne
- Investigative Site 6 - Uzhhorod
- Investigative Site 7 - Zaporizhzhya
Florida
- Investigative Site 2 - Hialeah
Missouri
- Investigative Site 1 - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992261
The ClinicalTrials.gov registry entry for NCT03992261 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is Mayne Pharma International Pty, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Halobetasol Topical Foam is the first listed.
NCT03992261 reports 11 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT03992261 about?
NCT03992261 is a clinical study titled "Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis". The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.
What is the current status of trial NCT03992261?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2019-06-14. Estimated completion is 2019-12-30.
What conditions does trial NCT03992261 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT03992261?
The interventions under investigation include: Halobetasol Topical Foam (DRUG).
Who is sponsoring clinical trial NCT03992261?
This trial is sponsored by Mayne Pharma International Pty, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992261 being conducted?
This trial has 11 study locations across Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
-
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
COMPLETED · Phase 4
-
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.